Individuals with type-2 diabetes are more likely to have a heart attack or stroke, as well as progressive renal damage. However, recent research suggests that efpeglenatide, a once-weekly injectable medication, might significantly lower their chances of these consequences.
Safe And Effective Way To Reduce Cardiorenal Events For Individuals With Type 2 Diabetes
The research trial spanned 28 countries and included approximately 4,000 type-2 diabetes patients.
Patients who got weekly efpeglenatide injections had a 27% reduced risk of a heart attack, stroke, cardiovascular-related mortality, or death from any cause, as well as a 32% lower risk of renal disease progression, compared to those who received a placebo.
The study, which the drug’s manufacturer, Sanofi, financed, was presented Monday at the American Diabetes Association’s (ADA) virtual annual conference and was published concurrently in the New England Journal of Medicine.
According to research main author Dr. Hertzel Gerstein, professor at McMaster University and Hamilton Health Sciences in Hamilton, Canada, the trial validates efpeglenatide as an effective cardioprotective medication for type 2 diabetes patients with cardiovascular and/or renal illness.
They are delighted that this once-week injection decreased cardiovascularly and kidney disease development in individuals with long-standing diabetes who had a high incidence of cardiovascular and renal illness, he stated in an ADA press release.
According to the researchers, efpeglenatide belongs to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RA), which are used to treat diabetes and lower blood sugar levels, weight, and blood pressure.
The previous study has indicated that GLP-1 RA medications that target GLP-1 can help with heart and renal issues.
That is no minor achievement for the more than 32 million Americans who have diabetes. According to the researchers, the vast majority (98 percent) of individuals with type-2 diabetes have at least one additional chronic illness, such as heart or renal disease.
One-quarter (24%) of type 2 diabetes patients have renal disease, 22% have cardiovascular disease, and 82% have hypertension, which is a significant cause of heart disease.
Gerstein’s team examined results for patients with type-2 diabetes in the latest research study. Patients were given efpeglenatide either alone or in combination with a drug from another frequently used family of medications known as SGLT2 inhibitors.
The advantages of efpeglenatide were comparable with or without the usage of an SGLT2 inhibitor medication, according to the researchers. There were no significant adverse effects from using the medication.
The AMPLITUDE O study involved almost 4,000 people with type 2 diabetes from 28 different countries. Over two years, individuals given weekly injections of efpeglenatide vs placebo had a 27% lower risk of a heart attack, stroke, or cardiovascular mortality; a 32% lower risk of renal disease progression; and a 27% lower risk of a heart attack, stroke, or death from any cause. The results were similar in the presence and absence of an SGLT2 inhibitor. There were no significant adverse effects.
The findings were positive, according to two diabetes care professionals who were not engaged in the study.
Dr. Minisha Sood, an endocrinologist at Lenox Hill Hospital in New York City, said the average patient in the trial resembles the typical individual with type-2 diabetes in the United States, despite the risk of heart and renal issues.
She did point out one problem in the trial: it only compared efpeglenatide to placebo and not to high-dose semaglutide (Ozempic), another effective medication commonly used in this kind of patient.
Dr. Barbara Keber is the family medicine director of Glen Cove Hospital in Glen Cove, New York. According to her, the latest experiment demonstrated that efpeglenatide is both effective and safe.
This is significant, according to Keber, because previous medicines that have improved cardiovascular disease have increased adverse effects.
Then there’s the matter of convenience.
According to Keber, the weekly injection has the advantage of requiring fewer injections, which makes it simpler for the patient. Weekly timing also lowers the risk of hypoglycemia (low blood sugar) and enables better management with the GLP1 RA medication. As a result, it is safer for individuals who would otherwise experience hypoglycemia with insulin or other medications when strict control is tried, she claims.